Patents by Inventor Nick Giannoukakis

Nick Giannoukakis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES
    Publication number: 20210401884
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Application
    Filed: February 3, 2021
    Publication date: December 30, 2021
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
    Patent number: 10940164
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: March 9, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES
    Publication number: 20190321398
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Application
    Filed: March 8, 2019
    Publication date: October 24, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
    Patent number: 10272112
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: April 30, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus
    Patent number: 10105334
    Abstract: Particle formulations are disclosed that include polymeric particles containing a small molecule drug and a high molecular weight therapeutic protein. Methods of making and using the particle formulations also are disclosed. These particle formulations are of use to treat an autoimmune disease, such as diabetes, or an inflammatory disease.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: October 23, 2018
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Duquesne University
    Inventors: Nick Giannoukakis, Massimo M. Trucco, Wilson S. Meng
  • MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES
    Publication number: 20170360834
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Application
    Filed: June 27, 2017
    Publication date: December 21, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
    Patent number: 9724365
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: August 8, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • PARTICLE FORMULATIONS OF ALL-TRANS RETINOIC ACID AND TRANSFORMING GROWTH FACTOR BETA FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS
    Publication number: 20160338984
    Abstract: Particle formulations are disclosed that include polymeric particles containing a small molecule drug and a high molecular weight therapeutic protein. Methods of making and using the particle formulations also are disclosed. These particle formulations are of use to treat an autoimmune disease, such as diabetes, or an inflammatory disease.
    Type: Application
    Filed: January 16, 2015
    Publication date: November 24, 2016
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Duquesne University
    Inventors: Nick Giannoukakis, Massimo M. Trucco, Wilson S. Meng
  • TOLEROGENIC DENDRITIC CELLS TO TREAT INFLAMMATORY BOWEL DISEASE
    Publication number: 20160230174
    Abstract: Methods are disclosed herein for treating or preventing an inflammatory bowel disease in a subject. These methods include administering to a subject an effective amount of tolerogenic dendritic cells, wherein the tolerogenic dendritic cells comprise at least one of an antisense compound specific for CD40, and antisense compound specific for CD80 and an antisense compound specific for CD86.
    Type: Application
    Filed: September 26, 2014
    Publication date: August 11, 2016
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
    Patent number: 9115357
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: August 25, 2015
    Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA, UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larry R. Brown, Vered Bisker-Leib, Terrence L. Scott, Debra Lafreniere, Jennifer Machen, Nick Giannoukakis
  • MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES
    Publication number: 20150139965
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
    Patent number: 8389493
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Grant
    Filed: May 9, 2011
    Date of Patent: March 5, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA, University of Pittsburgh—of The Commonwealth System of Higher Education
    Inventors: Larry R. Brown, Nick Giannoukakis, Kimberly A. Gillis, Massimo Trucco
  • OLIGONUCLEOTIDES TARGETING ASTHMA INFLAMMATION PROCESSES
    Publication number: 20120141549
    Abstract: The present invention relates to methods and compositions for inhibiting inflammatory processes (such as asthma) in the lungs, wherein oligonucleotides targeting IgE receptors and NfkappaB are administered via an aerosolized microsphere formulation.
    Type: Application
    Filed: October 25, 2011
    Publication date: June 7, 2012
    Inventors: Nick Giannoukakis, Massimo Trucco, Wilson Meng
  • MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES
    Publication number: 20110274758
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Application
    Filed: May 9, 2011
    Publication date: November 10, 2011
    Applicants: BAXTER INTERNATIONAL INC., University of Pittsburgh - Of the Commonwealth System of Higher Education, BAXTER HEALTHCARE S.A.
    Inventors: Larry R. Brown, Nick Giannoukakis, Kimberly A. Gillis, Massimo Trucco
  • Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
    Patent number: 8022046
    Abstract: A method is provided that includes using an antisense approach to reverse and/or delay an autoimmune diabetes condition in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Grant
    Filed: April 20, 2009
    Date of Patent: September 20, 2011
    Assignees: Baxter International, Inc., University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Larry R. Brown, Nick Giannoukakis, Massimo Trucco
  • Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
    Patent number: 7964574
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: June 21, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A., University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Larry R. Brown, Nick Giannoukakis, Kimberly A. Gillis, Massimo Trucco
  • DELIVERY OF AS-OLIGONUCLEOTIDE MICROSPHERES TO INDUCE DENDRITIC CELL TOLERANCE FOR THE TREATMENT OF AUTOIMMUNE TYPE 1 DIABETES
    Publication number: 20100260855
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Application
    Filed: June 24, 2010
    Publication date: October 14, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A., University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Larry R. Brown, Vered Bisker-Leib, Terrence L. Scott, Debra Lafreniere, Jennifer Machen, Nick Giannoukakis
  • MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES
    Publication number: 20090291145
    Abstract: A method is provided that includes using an antisense approach to reverse and/or delay an autoimmune diabetes condition in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Application
    Filed: April 20, 2009
    Publication date: November 26, 2009
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A., UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larry R. Brown, Nick Giannoukakis, Massimo Trucco
  • MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES
    Publication number: 20080039369
    Abstract: AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 14, 2008
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Larry Brown, Nick Giannoukakis, Kimberly Gillis
  • Use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same
    Patent number: 6936468
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (DCs) and methods for the production of the tolerogenic DCs. In addition, the present invention provides a method for enhancing tolerogenicity in a host comprising administering the tolerogenic mammalian DCs of the present invention to the host. The tolerogenic DCs of the present invention comprise an oligodeoxyribonucleotide (ODN) which has one or more NF-?B binding sites. The tolerogenic DCs of the present invention may further comprise a viral vector, and preferably an adenoviral vector, which does not affect the tolerogenicity of the tolerogenic DCs when present therein. Enhanced tolerogenicity in a host is useful for prolonging foreign graft survival and for treating inflammatory related diseases, such as autoimmune diseases.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: August 30, 2005
    Assignee: University of Pittsburgh
    Inventors: Paul David Robbins, Lina Lu, Nick Giannoukakis